Skoči na glavni sadržaj

Izvorni znanstveni članak

https://doi.org/10.15836/ccar2021.257

Vrijednosti serumskog kreatinina, Cockcroft-Gault i Modification of Diet in Renal Diseases jednadžbi u bolesnika s arterijskom hipertenzijom

Damir Šečić orcid id orcid.org/0000-0002-2116-7892
Adnan Turohan orcid id orcid.org/0000-0002-3557-4923
Edin Begić
Šekib Sokolović orcid id orcid.org/0000-0001-6321-4186
Damir Rebić orcid id orcid.org/0000-0003-4296-9453
Ehlimana Mušija orcid id orcid.org/0000-0002-5667-0279
Jasna Kusturica orcid id orcid.org/0000-0002-4120-7230
Aida Kulo Ćesić orcid id orcid.org/0000-0002-5891-3780
Esad Pepić orcid id orcid.org/0000-0002-4957-3868
Jasmin Mušanović orcid id orcid.org/0000-0002-2900-9397
Azra Metović orcid id orcid.org/0000-0003-2305-4995


Puni tekst: hrvatski pdf 302 Kb

str. 257-263

preuzimanja: 689

citiraj

Puni tekst: engleski pdf 302 Kb

str. 257-263

preuzimanja: 160

citiraj

Preuzmi JATS datoteku


Sažetak

Cilj: utvrditi postoje li razlike između vrijednosti kreatinina u serumu, procijenjene stope glomerularne filtracije (eGFR) prema jednadžbi Modification of Diet in Renal Disease (MDRD), klirensa kreatinina i eGFR-a dobivenih Cockcroft- Gault metodom s obzirom na dob, stupanj i trajanje arterijske hipertenzije (AH).
Bolesnici i metode: istraživanje je obuhvatilo 124 ambulantna bolesnika s AH-om pregledana na Klinici za bolesti srca, krvnih žila i reumatizam Kliničkog centra Univerziteta u Sarajevu. Pregledani su svi bolesnici te su uzeti podatci o trajanju i stupnju AH-a. Bubrežna je funkcija ocijenjena na osnovi serumskog kreatina, procijenjene su stope glomerularne filtracije prema MDRD jednadžbi, klirensom kreatinina procijenjenim Cockcroft-Gault jednadžbom (eCrClCG) i njegovim korekcijama za površinu tijela (eCrClCG1,73), za indeks tjelesne mase (eCrClCGBMI), indeks tjelesne mase i površinu tijela (eCrClCGBMI1,73) i procijenjeni GFR primjenom Cockcroft-Gault metode (eGFRCGBMI1,73).
Rezultati: nađena je značajna razlika u vrijednostima procijenjenog GFR-a MDRD jednadžbom, eCrClCGBMI, eCrClCGBMI1,73 i eGFRCGBMI1,73 u bolesnika s različitim stupnjevima i trajanjem AH-a, što nije dobiveno analizom vrijednosti serumskog kreatinina.
Zaključak: procijenjeni GFR i eCrCl osjetljiviji su biljezi oštećenja bubrega od vrijednosti kreatinina u serumu i njihovo određivanje treba biti uvedeno kao rutinski probir u otkrivanju ranih stadija kronične bubrežne bolesti u primarnoj zdravstvenoj zaštiti, posebno u bolesnika s AH-om.

Ključne riječi

stopa glomerularne filtracije; kardiovaskularne bolesti; probir; primarna zdravstvena zaštita.

Hrčak ID:

259370

URI

https://hrcak.srce.hr/259370

Datum izdavanja:

24.6.2021.

Podaci na drugim jezicima: engleski

Posjeta: 1.381 *




Introduction

The National Kidney Foundation defines chronic kidney disease as kidney damage that lasts for more than 3 months and is caused by structural or functional disorders of the kidneys, with or without a decrease in glomerular filtration rate (GFR), manifesting as histological abnormalities or disturbances in blood, urine, or kidney function. The term “chronic kidney failure” is used to describe the terminal (fifth) stage of chronic kidney disease. (1) Chronic kidney disease is one of the leading causes of mortality and morbidity in the world. (1-3) The prevalence of kidney disease has been constantly increasing over the last decade, in parallel with the rapid increase in diabetes mellitus and arterial hypertension, representing a major public health problem with enormous impact on quality of life and economic status. (1,4,5)

Early detection and treatment reduce the progression of chronic kidney disease toward end-stage kidney failure. (6-8) The most common causes of morbidity and mortality in patients with chronic kidney disease are cardiovascular ones. (9) Arterial hypertension can cause glomerular damage, microalbuminuria, and proteinuria. (3-5) Increase in blood pressure is associated with a significant decrease in GFR (1.1-6.2 mL/min/year). (6) Therapy with angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) has shown a renoprotective effect and reduction in proteinuria in patients with arterial hypertension. (5) This renoprotective effect is based on the blockage of the conversion of angiotensin I to angiotensin II and the consequent dilatation of the efferent arterioles and reduction of intraglomerular pressure. (7,10,11)

Early detection of kidney disease with the use of screening tests to reveal high-risk groups of patients, such as those with arterial hypertension and diabetes mellitus, is very important and cost-effective. (12-14) Creatinine clearance values always refer to the average body surface area of adults (1.73 m2), but because body surface area differs significantly between obese and slim individuals, creatinine values need to be corrected for actual body surface area. (4) In clinical practice, estimation of GFR is widely accepted as the best indicator of kidney function. (13) Normal GFR in young adults is greater than 90 mL/min/1.73 m2, averaging 125 mL/min/1.73 m2. (1) Measurement of creatinine and inulin clearance is used to assess GFR. (1) Assessment of kidney function can be done using glomerular filtration, according to the MDRD (Modification of Diet in Renal Disease Study) equation, while clearance of creatinine is determined by the Cockcroft-Gault method (eCrClCG) and its correction for body surface area (eCrClCG1.73). (1,5,12,13) Additionally, creatinine clearance determined by the Cockcroft-Gault method corrected for body mass index (eCrClCGBMI) and body surface area (eCrClCGBMI1.73) and estimated GFR using the Cockcroft-Gault method (eGFRCGBMI1.73) can be used for assessment of kidney function. (1,5,13)

The aim of this study was to determine whether there are differences between serum creatinine levels, estimated GFR according to the MDRD equation, creatinine clearance, and estimated GFR obtained by the Cockcroft-Gault method related to age, stage, and duration of arterial hypertension.

Patients and Methods

Patients and study design

This cross-sectional study was conducted in the Clinic for Heart, Rheumatism and Blood Vessels, Clinical Center University of Sarajevo, during March 2019. The study included 124 inpatients (n=124) with a diagnosis of arterial hypertension. Among other anamnestic data collected during physical examination, data was also collected from patient medical records on the cause, duration, and stage of arterial hypertension, as well as on antihypertensive therapy and smoking habits.

Criteria for inclusion in the study were: more than 18 years old, diagnosis of arterial hypertension, and measured serum creatinine values during the examination. Criteria for exclusion were: pre-existing diagnosis of chronic kidney disease of non-hypertensive ethology of any stage, chronic dialysis, diagnosis of acute and chronic heart failure, amputation of lower extremities, presence of active cancer or cancer in the anamnestic data, and pregnancy.

Ethical approval was obtained from the Ethical Committee, Clinical Center University of Sarajevo.

Methods

Assessment of the stage of arterial hypertension (grade I, II, and III) was performed based on the relevant guidelines for the management of arterial hypertension. (5)

Assessment of kidney function was performed with: serum creatinine levels (µmol/L), MDRD equation (mL/min/1.73 m2), eCrClCG (mL/min), eCrClCG1.73 (mL/min), eCrClCGBMI (mL/min), eCrClCGBMI1.73 (mL/min), and eGFRCGBMI1.73(mL/min/1.73 m2).

Statistical analysis

The results of the study were processed using descriptive and inferential statistics. The Kolmogorov-Smirnov test was used to assess the distribution of the data, and the data with the normal distribution was reported as arithmetic mean (X) and standard deviation (SD). Comparisons of numerical data between groups were done using the y Student’s t-test and one-way analysis of variance (ANOVA). The chi-square test of Independence and the Fisher’s exact test were used for evaluation of the association of categorical variables. All results of the statistical analysis at the level of p<0.05 were accepted as statistically significant.

Results

The study included 124 patients, of whom 60 (48.4%) were women with an average age of 63.1±8.15 and 64 (51.6%) men with an average age of 63.2±11.03. The majority of patients, i.e. 56 (45.2%) of them, were 56-65 years old, of whom 29 were women and 27 were men. The lowest number of patients was in the 35-44 age group (7 of them) – of those 2 women and 5 men. There was a significant difference in sex distribution in the 76-85 age group (χ2=4.818, p<0.05). Analysis of pharmacological status indicated that the vast number of patients with hypertension (n=88) used different types of antihypertensive drugs, i.e. 60 patients used dual therapy with either an ACE inhibitor + diuretic or ARB + diuretic. Fifty five (44.3%) patients used an ACE inhibitor and were low-risk patients with mainly the first-stage arterial hypertension; 42 patients (33.8%) used calcium channel blockers (Table 1). Of 36 patients with both arterial hypertension and diabetes mellitus, 17 used a diuretic with an ACE inhibitor or ARB (Table 2). There was a significant difference in the usage of nitro-based products between patients with hypertension only and patients with both arterial hypertension and diabetes mellitus, i.e. patients with both diseases used nitro-based products more often (χ2=6.278; p<0.05).

TABLE 1 Distribution of patients according to duration and stage of arterial hypertension.
Hypertension
n (%)
Total number of patients (n=124)Duration of the disease (in years)
Mean ± SD
Hypertension duration<5 years49 (39.5%)2.3 ± 0.92
5-10 years43 (34.7%)7.3 ± 2.07
>10 years32 (25.8%)18.4 ± 8.39
Hypertension stageI56 (45.2%)6.8 ± 6.99
II56 (45.2%)8.8 ± 6.37
III12 (9.6%)12.3 ± 13.69
SD=standard deviation
TABLE 2 Frequency of usage of different drugs and drug combinations in the treatment of arterial hypertension in relation to the stage and duration of the disease.
CharacteristicAntihypertensive treatment
ACE inhibitorARBDiuretic+ACE inhibitor / Diuretic+ARBCa-blockerNitro-derivates
n (%)n (%)n (%)n (%)n (%)
DiseaseHTA39 (43.8%)10 (11.2%)43 (48.3%)30 (33.7%)43 (48.3%)
HTA/DM16 (45.7%)4 (11.4%)17 (48.6%)12 (34.3%)29 (82.9%)
Sexfemale26 (43.3%)8 (13.3%)27 (45.0%)24 (40%)31 (51.7%)
male29 (45.3%)6 (9.4%)33 (51.6%)18 (28.1%)41 (67.2%)
Age (years)35-453 (42.9%)0 (0.0%)4 (57.1%)2 (28.6%)4 (57.1%)
46-558 (61.5%)1 (7.7%)4 (30.8%)4 (30.8%)7 (53.8%)
56-6528 (50.0%)6 (10.7%)25 (44.6%)18 (32.1%)30 (53.6%)
66-7514 (38.9%)6 (16.7%)18 (50.0%)13 (36.1%)24 (66.7%)
76-852 (16.7%)1 (8.3%)9 (75.0%)5 (41.7%)7 (58.3%)
HTA duration (years)<527 (55.1%)5 (10.2%)20 (40.8%)10 (20.4%)26 (53.1%)
5-1017 (39.5%)6 (13.9%)19 (44.2%)16 (37.2%)29 (67.4%)
>109 (28.1%)3 (9.4%)21 (65.6%)16 (50.0%)17 (53.1%)
HTA stageI29 (51.8%)3 (5.4%)23 (41.1%)12 (21.4%)31 (55.4%)
II22 (39.3%)10 (17.8%)30 (53.6%)20 (35.7%)33 (58.9%)
III4 (33.3%)1 (8.3%)7 (58.3%)10 (83.3%)8 (66.7%)
SmokingYes41 (47.1%)9 (10.3%)41 (47.1%)34 (39.1%)54 (62.1%)
No14 (37.8%)5 (13.5%)19 (51.4%)8 (21.6%)18 (48.6%)
ACE inhibitor=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; Ca blocker=calcium blocker; HTA=hypertension; DM=diabetes mellitus

There was a significant relation between the eGFRCGBMI1.73 and the age (p=0.001) (Table 3). For each 10-year age increase, the average value of eGFRCGBMI1.73 decreased by 11.03 mL/min/1.73 m2. Additionally, with each 10-year age increase the average value of the estimated GFR with the MDRD formula decreased by 5.24 mL/min/1.73 m2. Furthermore, there was a significant difference in the values MDRD formula-estimated GFR, eCrClCGBMI, eCrClCGBMI1.73, and eGFRCGBMI1.73 in subjects with different stages and different average illness duration (Table 4). If serum creatinine was used, no significant difference was observed between groups regarding the progression of arterial hypertension.

TABLE 3 Evaluation of kidney function according to sex.
Kidney functionAll patients
(n=124)
Sexp
Women
(n=60)
Men
(n=64)
Serum creatinine (µmol/L)89.7 ± 20.4984.4 ± 20.9794.8 ± 19.020.005
MDRD (mL/min/1.73 m2)72.0 ± 18.2466.4 ± 16.2777.4 ± 18.650.001
eCrClCG (mL/min)82.5 ± 28.4972.3 ± 19.4392.2 ± 32.390.001
eCrClCG1.73 (mL/min)70.6 ± 19.4166.6 ± 15.3274.3 ± 22.200.027
eCrClCGBMI (mL/min)74.4 ± 24. 2765.6 ± 17.0482.6 ± 27.300.001
eCrClCGBMI1.73 (mL/min)63.4 ± 16.9660.2 ± 14.1066.5 ± 18.990.038
eGFRCGBMI1.73 (mL/min/1.73 m2)50.6 ± 19.0446.8 ± 15.8054.3 ± 21.290.030
MDRD=estimated glomerular filtration rate according to the MDRD (Modification of Diet in Renal Disease Study) equation; eCrClCG=clearance of creatinine estimated by the Cockcroft-Gault method; eCrClCG1.73=correction for body surface area; eCrClCGBMI=correction for body mass index; eCrClCGBMI1.73=correction for body surface area and body mass index; eGFRCGBMI1.73=estimated GFR using the Cockcroft-Gault method; p=level of significance
TABLE 4 Evaluation of kidney function according to sex in relation to the stage of arterial hypertension and average duration of disease.
Kidney functionAverage disease duration (in years)p
6.88.812.3
Disease stage
I (Mean ±SD)II (Mean ±SD)III (Mean ±SD)
Serum creatinine (µmol/L)87.0 ± 19.1992.1 ± 20.6891.9 ± 26.140.404
MDRD (mL/min/1.73 m2)76.5 ± 19.4268.8 ± 15.6566.0 ± 21.120.039
eCrClCG (mL/min)88.7 ± 29.4178.7 ± 25.7171.8 ± 33.660.071
eCrClCG1.73 (mL/min)75.1 ± 20.4567.4 ± 17.1564.8 ± 22.290.060
eCrClCGBMI (mL/min)80.5 ± 25.4070.0 ± 20.8366.9 ± 29.910.038
eCrClCGBMI1.73 (mL/min)68.1 ± 18.0059.8 ± 14.3059.2 ± 20.200.024
eGFRCGBMI1.73 (mL/min/1.73 m2)55.6 ± 20.1646.8 ± 16.2145.7 ± 22.740.031
MDRD=estimated glomerular filtration rate according to the MDRD (Modification of Diet in Renal Disease Study) equation; eCrClCG=clearance of creatinine estimated by the Cockcroft-Gault method; eCrClCG1.73=correction for body surface area; eCrClCGBMI=correction for body mass index; eCrClCGBMI1.73=correction for body surface area and body mass index; eGFRCGBMI1.73=estimated GFR using the Cockcroft-Gault method; p=level of significance; SD=standard deviation

Discussion

Research has shown that patients predominantly receive polytherapy for arterial hypertension, which is a trend in modern cardiology. (5) Classification of arterial hypertension in stages in relation to blood pressure values on examination is not an optimal clinical approach. Additionally, as demonstrated in this study, the duration of hypertension does not affect the stage of hypertension. The use of renoprotective and cardioprotective drugs is imperative. (5) Slower progression of kidney disease has been demonstrated in patients with diabetes mellitus and arterial hypertension if they used ACE inhibitors or ARBs. (14,15) When it is not possible to include one of these medications in the therapy, non-hydropyridine calcium channel blockers are recommended. (5) Therapy with ACE inhibitors and ARBs shows a renoprotective effect and reduction in proteinuria in patients with arterial hypertension. Combinations of ACE inhibitors and diuretics and ARBs and diuretics were the most-prescribed combinations. The National Kidney Foundation suggests the use of a fixed cut-off value of estimated GFR to define chronic kidney diseases, those values being GF<60 mL/min/1.73 m2 with a three-month chronicity. (16) This recommendation is not reasonable, as it does not take into account differences in age and sex, which are non-negotiable. Research has verified significant differences in the values of MDRD formula-estimated GFR, eCrClCGBMI, eCrClCGBMI1.73, and eGFRCGBMI1.73 in subjects with different stages and different average illness durations, which has not been demonstrated for serum creatinine. Rule et al. conducted a study on 365 potential kidney donors to define age- and sex-related reference values for GFR and serum creatinine values. (17) GFR was measured using iothalamate clearance, and the abbreviated MDRD equation (eGFR-MDRD) and the Cockcroft-Gault method were used for its estimation. (17) It decreased significantly with increased age and was much lower in women compared with men. The average estimated GFR of men whose average age was 20 was 129 mL/min with a decline of 4.6 mL/min per decade. In women of the same age, the estimated GFR was 123 mL/min with a decline of 7.1 mL/min/decade. GFR values corrected for body mass index were significantly different for age, but not for sex. (17) Additionally, patients who were on average 20 years old had a GFR of 111 mL/min/1.73 m2, with a decline of 4.9 mL/min/1.73 m2 with every decade. (17)

Velde et al. examined the correlation of estimated GFRs (for different methods and different age groups) and cardiovascular events in 8047 subjects. (18) The following equations were used to estimate GFR: the MDRD equation, the chronic kidney disease-epidemiology collaboration (CKD-EPI) equation, the cystatin C-based equation, the combined serum creatinine and cystatin C Quadratic Equation, and 24-hours creatinine clearance. (18) They concluded that all of the methods used to estimate GFR were significantly correlated with cardiovascular events in patients who are less than 60 years old, while 24-hour creatinine clearance showed a significant correlation with cardiovascular events in subjects who are 60 or more years old. Milojkovic et al. investigated the correlation between essential arterial hypertension and hypertensive nephropathy among 283 subjects as well as the prevalence of risk factors for the development of atherosclerotic changes. (19) A significant correlation was found between a positive anamnesis, arterial hypertension, smoking, and dyslipidemia in relation to the prevalence of hypertensive nephropathy. (19) The estimated GFR according to the MDRD equation was in a significant inversely proportional relationship with duration and stages of arterial hypertension, and the same relationship was found between eCrClCGBMI1.73 and eGFRCGBMI1.73 and the duration and stage of arterial hypertension. (19) Research has shown that the habit of smoking is still a large problem for patients in Bosnia and Herzegovina, and preventive programs aiming to reduce progression of atherosclerotic disease should be part of the daily work of medical doctors in primary health care.

The limitations of the present study were, firstly, the small number of patients used to assess optimal pharmacological treatment, and secondly, the treatment modality of diabetes mellitus was not taken into account, which could have affected the results. Additionally, distribution of ACE inhibitors or ARBs to individual patients while taking into account their pharmacodynamics and pharmacokinetic properties, would be an important approach in assessing the renoprotective effects of the drugs.

Conclusion

Estimated GFR and eCrCl are more sensitive markers of kidney impairment than serum creatinine values, and their assessment should be introduced as a routine screening in the detection of early stages of chronic kidney disease in primary care settings, especially in patients with arterial hypertension.

Notes

[1] Financial disclosure FUNDING: No specific funding was received for this study.

[2] Conflicts of interest TRANSPARENCY DECLARATION: Competing interests: none to declare.

LITERATURE

1 

National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation,classification, and stratification. Am J Kidney Dis. 2002 February;39(2) Suppl 1:S1–266. PubMed: http://www.ncbi.nlm.nih.gov/pubmed/11904577

2 

Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017 March;389:1238–52. https://doi.org/10.1016/S0140-6736(16)32064-5 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/27887750

3 

Pugh D, Gallacher PJ, Dhaun N. Management ofHypertension in Chronic Kidney Disease. Drugs. 2019 March;79(4):365–79. https://doi.org/10.1007/s40265-019-1064-1 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/30758803

4 

Hu KT, Matayoshi A, Stevenson FT. Calculation of the estimated creatinine clearance in avoiding drug dosing errors in the older patient. Am J Med Sci. 2001 September;322(3):133–6. https://doi.org/10.1097/00000441-200109000-00004 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/11570777

5 

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 September;39(33):3021–104. https://doi.org/10.1093/eurheartj/ehy339 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/30165516

6 

Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941–51. https://doi.org/10.1056/NEJMoa042167 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/15516697

7 

Sinha AD, Agarwal R. Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. Clin J Am Soc Nephrol. 2019 May;14(5):757–64. https://doi.org/10.2215/CJN.04330418 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/30425103

8 

Biljak VR, Honović L, Matica J, Knežević B, Vojak SŠ. Laboratory diagnostics of chronic kidney disease in Croatia: state of the art. Biochem Med (Zagreb). 2015 February;25(1):73–83. https://doi.org/10.11613/BM.2015.009 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25672470

9 

Mataradžija A, Resić H, Rašić S, Kukavica N, Mašnić F. Risk factors for development of cardiovascular complications in patients with chronic renal disease and diabetic nephropathy. Bosn J Basic Med Sci. 2010 Apr;10 Suppl 1(Suppl 1):S44-50. https://doi.org/ https://doi.org/10.17305/bjbms.2010.2648

10 

Noble E, Johnson DW. Automated laboratory reporting of estimated glomerular filtration rate: is it good for the health of patients and their doctors? Biochem Med (Zagreb). 2007 June;17(1):16–28. https://doi.org/10.11613/BM.2007.003

11 

Saracino A, Morrone LF, Suriano V, Niccoli-Asabella A, Ramunni A, Fanelli M, et al. A simple method for correcting overestimated glomerular filtration rate in obese subjects evaluated by the Cockcroft and Gault formula: a comparison with 51Cr EDTA clearance. Clin Nephrol. 2004 August;62(2):97–103. https://doi.org/10.5414/CNP62097 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/15356966

12 

Luke DR, Halstenson CE, Opsahl JA, Matzke GR. Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther. 1990 November;48(5):503–8. https://doi.org/10.1038/clpt.1990.186 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/2225710

13 

Johnson D. Evaluation of renal function: Classification of chronic kidney disease based on evaluation of kidney function. Nephrology (Carlton). 2005 October;10(4):S172–6. https://doi.org/10.1111/j.1440-1797.2005.00487_5.x

14 

Jack K-CNG, Philip K-TLI. Chronic Kidney disease: How do we deal with it? Nephrology (Carlton). 2018 October;23(4):116–20. https://doi.org/10.1111/nep.13464 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/30298662

15 

Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol. 2008 September;3(5):1511–25. https://doi.org/10.2215/CJN.04140907 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/18550651

16 

Poggio ED, Rule AD, Tanchanco R, Arrigain S, Butler RS, Srinivas T, et al. Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors. Kidney Int. 2009 May;75(10):1079–87. https://doi.org/10.1038/ki.2009.11 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/19212414

17 

Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, et al. Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis. 2004 January;43(1):112–9. https://doi.org/10.1053/j.ajkd.2003.09.026 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/14712434

18 

van der Velde M, Bakker SJ, de Jong PE, Gansevoort RT. Influence of age and measure of eGFR on the association between renal function and cardiovascular events. Clin J Am Soc Nephrol. 2010 November;5(11):2053–9. https://doi.org/10.2215/CJN.08851209 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/20705964

19 

Milojkovic B, Djindjic B, Radenkovic S, Kocic G, Milojkovic B. Essential arterial hypertension and risk factors associated with hypertensive nephropathy. Acta Medica Medianae. 2014;53(4):15–21. https://doi.org/10.5633/amm.2014.0403


This display is generated from NISO JATS XML with jats-html.xsl. The XSLT engine is libxslt.